mTOR as a therapeutic target in patients with gastric cancer. - Wikidata - wikimedia - TriplyDB

mTOR as a therapeutic target in patients with gastric cancer.

mTOR as a therapeutic target in patients with gastric cancer.

http://www.wikidata.org/entity/Q37928535

about

New advances in targeted gastric cancer treatment The Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal Cancer Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application mTOR, a new potential target for chronic pain and opioid-induced tolerance and hyperalgesia The critical role of Akt in cardiovascular function Opioid receptor-triggered spinal mTORC1 activation contributes to morphine tolerance and hyperalgesia Genetic mutation analysis of human gastric adenocarcinomas using ion torrent sequencing platform.A polymorphism (rs2295080) in mTOR promoter region and its association with gastric cancer in a Chinese population Combination of carbonic anhydrase inhibitor, acetazolamide, and sulforaphane, reduces the viability and growth of bronchial carcinoid cell lines.Spinal cord NMDA receptor-mediated activation of mammalian target of rapamycin is required for the development and maintenance of bone cancer-induced pain hypersensitivities in rats.mTOR inhibition in management of advanced breast cancer.Rapamycin and WYE-354 suppress human gallbladder cancer xenografts in mice mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice mTOR and its downstream pathway are activated in the dorsal root ganglion and spinal cord after peripheral inflammation, but not after nerve injury Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma.Blocking mammalian target of rapamycin alleviates bladder hyperactivity and pain in rats with cystitis.Blocking mammalian target of rapamycin (mTOR) improves neuropathic pain evoked by spinal cord injury.Impacts of the mTOR gene polymorphisms rs2536 and rs2295080 on breast cancer risk in the Chinese population.DDX5 promotes gastric cancer cell proliferation in vitro and in vivo through mTOR signaling pathway Targeted therapy for gastric cancer.Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition.Recent advances and future trends in the targeted therapy of metastatic gastric cancer.The Gene Expression Status of the PI3K/AKT/mTOR Pathway in Gastric Cancer Tissues and Cell Lines.Celecoxib sensitizes gastric cancer to rapamycin via inhibition of the Cbl-b-regulated PI3K/Akt pathway.Inhibition of mTOR signalling potentiates the effects of trichostatin A in human gastric cancer cell lines by promoting histone acetylation.Carnosine Inhibits the Proliferation of Human Gastric Carcinoma Cells by Retarding Akt/mTOR/p70S6K Signaling.Blocking mammalian target of rapamycin alleviates bone cancer pain and morphine tolerance via µ-opioid receptor.Dramatic antitumor effects of the dual mTORC1 and mTORC2 inhibitor AZD2014 in hepatocellular carcinoma.Celastrol induces cell cycle arrest by MicroRNA-21-mTOR-mediated inhibition p27 protein degradation in gastric cancer.Targeting mTORC2 component rictor inhibits cell proliferation and promotes apoptosis in gastric cancer.The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance.Rapamycin inhibits the invasive ability of thyroid cancer cells by down-regulating the expression of VEGF-C in vitro.Angiogenesis inhibitors in early development for gastric cancer.Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.Involvement of pro-inflammation signal pathway in inhibitory effects of rapamycin on oxaliplatin-induced neuropathic pain.miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in gastric cancer through regulation of the PI3K/AKT/mTOR pathway.Knockdown of RAI14 suppresses the progression of gastric cancer Whole-genome sequencing of esophageal adenocarcinoma in Chinese patients reveals distinct mutational signatures and genomic alterations

P2860

Q26738548-F5E8F1F6-B431-40A8-B060-EC5045765E31 Q26744721-412A3203-B1BB-4309-B581-CAA90B153470 Q26765941-44D26656-6880-4691-B472-CB858A952A9F Q28081540-BBAC0A45-F3E7-408A-A236-C85E94124382 Q28083829-E93C252F-AE13-4EC9-BB9B-FFA097ED7751 Q28576512-69B28096-58B9-4954-A9DB-4AE28599FBE1 Q33903687-02B085B3-96BB-446F-B795-718F50E524A2 Q34653205-D69BB6A8-467B-4C02-AEBF-6F112E8A8F79 Q34911416-4C12D61F-E6AB-4774-9650-A40212B6448C Q35874744-31758868-E35F-48BE-9216-CD12572D7CEC Q36228145-71DD625A-04B1-4449-86C1-F21B8B903C81 Q36544718-B19EF978-57FA-4D4B-9A0E-9BBF972866AB Q36580462-E54322BF-7425-4B28-A42A-C8C9052ED590 Q36843926-FD00D487-66D8-4946-8A9E-12D336452537 Q36977421-E4F0623D-B7EF-4733-A9EE-FA3BB580E044 Q37375064-B645E169-935A-44D8-871D-C1B26A45F62F Q37585446-56EF67FE-5826-4E36-AA25-33C1D223B4DE Q37629003-3DAA5F9A-1F49-4135-BA5B-6FD2DB89FF8B Q37652251-8B76E681-6FBF-4BEC-854E-15C58AFC508C Q38007119-8052D840-7105-42EF-8122-61925AE55C7E Q38155511-A51C6A05-B2D9-48C5-88B3-1EB6612A04C8 Q38199128-A351F347-1DAC-4E0D-90AE-7AD9D3D9C5D6 Q38772498-C886A5CC-059C-4D45-9098-8769206B8E77 Q38907631-E0416986-6EE7-4369-8A0B-DE850C070091 Q39096573-15DF79C9-1B5D-4054-9138-F8428FFD4DC0 Q39147611-B281CA4D-9D1D-4F6E-BE4C-413471906E87 Q40323078-79731D0E-20D9-4EBB-90E3-793F4B954BBD Q42027870-405709A9-C58D-418A-B994-A8E4DD5DA8D2 Q42061952-2CFEA3E1-65F1-4E7F-82B3-F94B7E0A594A Q42068002-5677CF02-BFF9-47CF-B41A-4178DD7D2049 Q44802535-1F3F626D-9606-48CF-B446-F6FC149C93A6 Q46393415-4BD4B123-8A1D-47D7-AA89-9D32DB236821 Q47996955-293DA373-A1E5-40CB-9BBF-453EF1218402 Q48522177-89D3CEDD-6C0E-4B67-A3AD-F4560421BFC6 Q52627434-3402D5CF-0ECF-4E48-92DB-4341BC0FDEDF Q53314337-C6E99B65-29A6-4ED5-B182-6C64A4E108D7 Q57817288-B777544B-7A57-4FD3-9287-A2757FD733F0 Q58118126-978AD956-F6AA-40B8-ABC6-B2A49C23B63F

P2860

mTOR as a therapeutic target in patients with gastric cancer.

http://www.wikidata.org/entity/Q37928535

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

mTOR as a therapeutic target in patients with gastric cancer.

@en

mTOR as a therapeutic target in patients with gastric cancer.

@nl

type

label

mTOR as a therapeutic target in patients with gastric cancer.

@en

mTOR as a therapeutic target in patients with gastric cancer.

@nl

prefLabel

mTOR as a therapeutic target in patients with gastric cancer.

@en

mTOR as a therapeutic target in patients with gastric cancer.

@nl

P1433

Q37928535-869BBB2A-AC46-4861-8CC7-0E103C4C3C22

P1476

Q37928535-5C2F276D-AFBE-4792-9F0F-D8DF733027C3

P2093

Q37928535-10C5F764-9A1E-416C-8980-369AB5A51B67

Q37928535-325918E9-4F2F-49B0-9EFC-A885514B18C3

Q37928535-D9583AAC-D619-4B25-98D5-35117F282F58

P2860

Q37928535-064AD6F4-8331-4451-B69E-C4AAEF658E9D

Q37928535-069E8340-7098-453A-9955-8E4AB12471EF

Q37928535-0BE35075-BD94-4F69-8EA0-483883DD8B32

Q37928535-0DF83765-A580-4715-AC22-131B2435D33E

Q37928535-0E2740A7-7C3B-462A-829A-D767DDE1C2C3

Q37928535-150FEFCA-9204-44A9-BF9C-49C69FC8BB9E

Q37928535-198D9DFC-3555-4BDC-B80B-1E775A2996BF

Q37928535-19AB4A72-4BA5-436A-8F86-9D9E7FBB95FE

Q37928535-1AE25834-4DC8-419E-A501-D4ADF5B533F2

Q37928535-22950455-7114-4297-A377-35C1F5FE6967

P304

Q37928535-39E67237-D229-4ED8-ADCC-AADB878F5553

P31

Q37928535-BD72ACD3-685D-4B89-BC39-9A3C29CB809A

P356

Q37928535-52228DCF-3BB4-48CB-A14E-DE1B8B652C18

P433

Q37928535-96AA98B1-C8B7-4737-B43E-C71CB3E44742

P478

Q37928535-7B8A8A02-5747-42B3-8C04-17B291493A01

P577

Q37928535-A461E9B5-A39E-4098-ABBC-E46D66D59D4F

P5875

Q37928535-CCD661DA-FC1A-45D5-8BB5-1112AA3A5193

P698

Q37928535-20C86EE7-6B7A-4081-AB77-A188190D1DB6

P921

Q37928535-CB3ADD9C-618F-4EDF-9809-D92C10A46B3C

P356

P1433

International Journal of Cancer

P1476

mTOR as a therapeutic target in patients with gastric cancer.

@en

P2093

Atsushi Ohtsu

http://www.w3.org/2001/XMLSchema#string

Michel Ducreux

http://www.w3.org/2001/XMLSchema#string

Salah-Eddin Al-Batran

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations of PIK3CA in gastric adenocarcinoma

mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

mTOR: from growth signal integration to cancer, diabetes and ageing

Targeting the mTOR signaling network for cancer therapy

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

TOR signaling in growth and metabolism

P304

491-496

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.26396

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

130

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51625456

http://www.w3.org/2001/XMLSchema#string

P698

21898386

http://www.w3.org/2001/XMLSchema#string

P921